View Older Stories
-
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
-
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026
-
Jefferies Downgrades Amphastar Pharmaceuticals (AMPH) to Hold
-
Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference
-
Amphastar Pharmaceuticals (AMPH) PT Lowered to $30 at Needham
-
Amphastar Pharma (AMPH) Misses Q4 EPS by 20c
-
Amphastar receives FDA approval for generic respiratory drug
-
Amphastar Announces FDA Approval for Ipratropium Bromide HFA
-
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
-
Amphastar licenses synthetic hormone compound for $91 million deal
-
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
-
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
-
Amphastar receives FDA approval for generic teriparatide injection
-
Amphastar Announces FDA Approval for Teriparatide Injection
-
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
-
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
-
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
-
Amphastar enters $2.8 million research agreement with Hanxin
-
Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference
-
Needham Upgrades Amphastar Pharmaceuticals (AMPH) to Buy
-
Amphastar licenses three peptide drugs from Nanjing Anji for $453 million
-
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
-
Amphastar receives FDA approval for generic iron sucrose injection
-
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
-
Amphastar Pharmaceuticals (AMPH) PT Lowered to $25 at Piper Sandler
-
Amphastar Pharma (AMPH) Tops Q2 EPS by 11c
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
-
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025
-
Amphastar plans to quadruple manufacturing capacity at California facility
-
Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters
-
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
-
JPMorgan Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral
-
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
-
Amphastar Pharma (AMPH) Tops Q1 EPS by 5c
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
-
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
-
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
-
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
-
Amphastar Pharmaceuticals (AMPH) PT Lowered to $32 at Piper Sandler; 'A Tough 2025 Ahead'
-
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
-
Amphastar Pharma (AMPH) Misses Q4 EPS by 5c
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
-
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
-
Piper Sandler Downgrades Amphastar Pharmaceuticals (AMPH) to Neutral
-
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
-
Wells Fargo Starts Amphastar Pharmaceuticals (AMPH) at Overweight
-
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
-
Amphastar Pharma (AMPH) Misses Q3 EPS by 4c

